<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00031551</url>
  </required_header>
  <id_info>
    <org_study_id>020133</org_study_id>
    <secondary_id>02-NR-0133</secondary_id>
    <nct_id>NCT00031551</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury</brief_title>
  <official_title>Evaluation of Efficacy and Mechanisms of an Anti-Inflammatory Intervention for Chemotherapy Related Mucosal Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consisted of two parts: the pilot study and the main study. The purpose of the
      pilot study is to demonstrate the effectiveness of planned laboratory techniques to assess
      for TNF-alpha gene expression from unstimulated saliva, plasma, and mucosal epithelial cells
      in patients who have chemotherapy-related stomatitis.

      Main Study Description: Stomatitis is defined as inflammation of the mucous membranes of the
      oral cavity and oropharynx characterized by tissue erythema, edema, and atrophy, often
      progressing to ulceration. Stomatitis is a biologically complex, multifactorial, cancer
      treatment-related oral condition experienced by many oncology patients, which often leads to
      a cascade of negative sequelae including oropharyngeal pain, critical treatment alterations
      or cessation, and decreased quality of life. The optimal treatment strategies for stomatitis
      have not been established. There is a critical need to examine the pathogenesis of and to
      evaluate interventions for stomatitis and related acute oropharyngeal pain in the randomized
      controlled clinical trial setting using valid and reliable stomatitis assessment tools to
      both advance the science of cancer treatment-related oral toxicities and improve patient
      care. Therefore, the purpose of this randomized controlled clinical trial is to elucidate the
      role of inflammation in stomatitis by testing the effects of a novel tumor necrosis factor
      (TNF) fusion protein etanercept, (Enbrel, Immunex Corporation, Seattle, WA) on the incidence
      and severity of stomatitis. The actions of this fusion protein, which binds specifically to
      TNF preventing its interaction with cellular receptors and altering the inflammatory cascade,
      may provide insight into the role of inflammation in stomatitis. An etanercept effect is
      defined as a prevention or amelioration of stomatitis and acute oropharyngeal pain and/or
      changes in levels of tissue mediators. If stomatitis is primarily a consequence of a mucosal
      inflammatory response, then we hypothesize that this oral condition will be responsive to
      binding of TNF(alpha). Elaboration of the role of inflammatory cell signaling associated with
      stomatitis and the effect of TNF(alpha) may elucidate the mechanisms related to the
      pathogenesis of stomatitis and to other mucosal conditions.

      Patients who are scheduled to receive autologous or allogenic peripheral blood stem cell or
      bone marrow transplant will be invited to participate in this study during a regularly
      scheduled pre-treatment visit. Written informed consent will be obtained from all
      participants. Patients will be randomized to receive either etanercept mouthwash or placebo,
      which will both be administered by protocol schedule. Stomatitis and oropharyngeal pain will
      be measured at baseline and at specified post-chemotherapy time points corresponding with the
      predicted stomatitis onset, peak, and healing time course. TNF(alpha) levels in buccal
      mucosa, analyzed by reverse transcriptase polymerase chain reaction techniques, and blood
      levels of pro-inflammatory cytokines, growth factors, and inflammatory mediators will also be
      measured at baseline and at specified post-chemotherapy time points corresponding with the
      predicted stomatitis onset, peak, and healing time course.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of two parts: the pilot study and the main study. The purpose of the
      pilot study is to demonstrate the effectiveness of planned laboratory techniques to assess
      for TNF-alpha gene expression from unstimulated saliva, plasma, and mucosal epithelial cells
      in patients who have chemotherapy-related stomatitis.

      Main Study Description: Stomatitis is defined as inflammation of the mucous membranes of the
      oral cavity and oropharynx characterized by tissue erythema, edema, and atrophy, often
      progressing to ulceration. Stomatitis is a biologically complex, multifactorial, cancer
      treatment-related oral condition experienced by many oncology patients, which often leads to
      a cascade of negative sequelae including oropharyngeal pain, critical treatment alterations
      or cessation, and decreased quality of life. The optimal treatment strategies for stomatitis
      have not been established. There is a critical need to examine the pathogenesis of and to
      evaluate interventions for stomatitis and related acute oropharyngeal pain in the randomized
      controlled clinical trial setting using valid and reliable stomatitis assessment tools to
      both advance the science of cancer treatment-related oral toxicities and improve patient
      care. Therefore, the purpose of this randomized controlled clinical trial is to elucidate the
      role of inflammation in stomatitis by testing the effects of a novel tumor necrosis factor
      (TNF) fusion protein etanercept, (Enbrel) (Registered Trademark), Immunex Corporation,
      Seattle, WA) on the incidence and severity of stomatitis. The actions of this fusion protein,
      which binds specifically to TNF preventing its interaction with cellular receptors and
      altering the inflammatory cascade, may provide insight into the role of inflammation in
      stomatitis. An etanercept effect is defined as a prevention or amelioration of stomatitis and
      acute oropharyngeal pain and/or changes in levels of tissue mediators. If stomatitis is
      primarily a consequence of a mucosal inflammatory response, then we hypothesize that this
      oral condition will be responsive to binding of TNFa. Elaboration of the role of inflammatory
      cell signaling associated with stomatitis and the effect of TNFa may elucidate the mechanisms
      related to the pathogenesis of stomatitis and to other mucosal conditions.

      Patients who are scheduled to receive autologous or allogeneic peripheral blood stem cell or
      bone marrow transplant will be invited to participate in this study during a regularly
      scheduled pre-treatment visit. Written informed consent will be obtained from all
      participants. Patients will be randomized to receive either etanercept 2.5mg in 20cc
      mouthwash or placebo 20cc mouthwash, which will both be administered by protocol schedule.
      Stomatitis and oropharyngeal pain will be measured at baseline and at specified
      post-chemotherapy time points corresponding with the predicted stomatitis onset, peak, and
      healing time course. TNFa levels in buccal mucosa, analyzed by real time polymerase chain
      reaction techniques, and blood levels of pro-inflammatory cytokines, growth factors, and
      inflammatory mediators will also be measured at baseline and at specified post-chemotherapy
      time points corresponding with the predicted stomatitis onset, peak, and healing time course.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    It was not feasible to recruit required sample size from two clinical sites.
  </why_stopped>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>What is the Clinical Efficacy of an Etanercept Mouthwash Used for the Treatment of Autologous or Allogeneic Peripheral Blood Stem Cell Transplant or Bone Marrow Transplant Treatment-related Stomatitis?</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical efficacy will be determined by measurement of stomatitis grade and oropharyngeal pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>What is the Toxicity of an Etanercept Mouthwash Used for the Treatment of Autologous or Allogeneic Peripheral Blood Stem Cell Transplant or Bone Marrow Transplant Treatment -Related Stomatitis?</measure>
    <time_frame>2 years</time_frame>
    <description>Toxicity will be measured by the incidence of adverse events.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pilot Study: Mean Ratings of Oral Mucositis-related Oropharyngeal Pain Intensity on Day 9 (+/- 24 Hours) After Conditioning Chemotherapy (CT)</measure>
    <time_frame>Day 9 (+/- 24 hours) after conditioning chemotherapy</time_frame>
    <description>Subjects rated pain using the Painometer, a hand-held tool with a visual analogue scale to rate overall pain intensity and a list of 14 sensory and 11 affective pain descriptors ranked by intensity values from 1 - 5. Subjects look at the list of sensory and affective words and select words that describe their pain, including Oral Pain and Oral Pain with Swallowing. . The weighted scores assigned to the words are added to obtain a pain intensity score for the sensory and the affective components. The overall pain intensity is measured on a visual analogue scale which has a range of 1 - 10 with high scores indicating higher pain intensity. The sensory and affective pain scores are otained by adding all of the respective intensity values. The range of possible sensory scores is from 0 - 48 and the range of possible affective scores is from 0 - 37. The sensory and affective scores may be added together to obtain the total pain intensity score, which may range from 0 - 85.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pilot Study: Percentage of Participants Using Word Descriptors of Sensory and Affective Pain Selected by Subjects on Day 9 (+/- 24 Hours) After Conditioning Chemotherapy</measure>
    <time_frame>day 9 (+/- 24 hours) after conditioning chemotherapy</time_frame>
    <description>Participants selected from 14 word descriptors of sensory (S) pain and 11 word descriptors of affective (A) pain.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Stomatitis</condition>
  <arm_group>
    <arm_group_label>Main Study: Etanercept Mouthwash</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Study: Placebo Mouthwash</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilot Study</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <arm_group_label>Main Study: Etanercept Mouthwash</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Main Study: Placebo Mouthwash</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Male or female oncology patients who are enrolled in participating stomatogenic
                  autologous or allogeneic PBSCT/BMT protocols, and are willing to participate in
                  this study concurrently

               2. Able to understand and sign protocol consent or assent

               3. Age 16 years or older

        EXCLUSION CRITERIA:

          1. Pregnant or lactating females

          2. Unable to follow oral rinsing directions

          3. Intubation

          4. Chronic use of medications confounding assessment of the inflammatory response
             (non-steroidal antiinflammatory drugs, antihistamines, and steroids- with the
             exception of decadron that is commonly used as an antiemetic in the PBSCT/BMT setting)

          5. Pre-existing oral infection or upper respiratory infection that might maximize the
             possibility of an infection or sepsis contributing to a drug-related adverse event

          6. Known hypersensitivity or allergic reaction to etanercept
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane M Fall-Dickson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Nursing Research, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Cancer Centers of the Carolinas</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2002-NR-0133.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Seto BG, Kim M, Wolinsky L, Mito RS, Champlin R. Oral mucositis in patients undergoing bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1985 Nov;60(5):493-7.</citation>
    <PMID>3903598</PMID>
  </reference>
  <reference>
    <citation>Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993 Sep 1;72(5):1612-7.</citation>
    <PMID>8348492</PMID>
  </reference>
  <reference>
    <citation>Dose AM. The symptom experience of mucositis, stomatitis, and xerostomia. Semin Oncol Nurs. 1995 Nov;11(4):248-55. Review.</citation>
    <PMID>8578032</PMID>
  </reference>
  <results_reference>
    <citation>Fall-Dickson JM, Ramsay ES, Castro K, Woltz P, Sport√©s C. Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation. Clin Ther. 2007;29 Suppl:2547-61. doi: 10.1016/j.clinthera.2007.12.004.</citation>
    <PMID>18164921</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2002</study_first_submitted>
  <study_first_submitted_qc>March 7, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2002</study_first_posted>
  <results_first_submitted>November 24, 2015</results_first_submitted>
  <results_first_submitted_qc>November 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2015</results_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stomatitis</keyword>
  <keyword>Oropharyngeal pain</keyword>
  <keyword>TNF</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Bone marrow transplantation</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Cancer</keyword>
  <keyword>Oral cavity</keyword>
  <keyword>Oral mucous membranes</keyword>
  <keyword>Randomized controlled clinical trial</keyword>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Main Study Participants</title>
          <description>Participants were randomized to one of the following two interventions but the study was not unblinded.
Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.</description>
        </group>
        <group group_id="P2">
          <title>Pilot Study</title>
          <description>Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrew due to chemotherapy effects</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Main Study Participants</title>
          <description>Participants were randomized to one of the following two interventions but the study was not unblinded.
Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.</description>
        </group>
        <group group_id="B2">
          <title>Pilot Study</title>
          <description>Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="54" upper_limit="64"/>
                    <measurement group_id="B2" value="46" lower_limit="32" upper_limit="68"/>
                    <measurement group_id="B3" value="NA">These numbers reflect two different populations in two different studies and were not analyzed together.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Some College</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College Graduate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graduate School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Breast Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin's Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hodgkin's Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Myeloma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer stage</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstaged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accelerated Phase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>What is the Clinical Efficacy of an Etanercept Mouthwash Used for the Treatment of Autologous or Allogeneic Peripheral Blood Stem Cell Transplant or Bone Marrow Transplant Treatment-related Stomatitis?</title>
        <description>Clinical efficacy will be determined by measurement of stomatitis grade and oropharyngeal pain.</description>
        <time_frame>2 years</time_frame>
        <population>Participants withdrew and analyses were terminated before any data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Study: Etanercept Mouthwash</title>
            <description>Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
Etanercept</description>
          </group>
          <group group_id="O2">
            <title>Main Study: Placebo Mouthwash</title>
            <description>Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>What is the Clinical Efficacy of an Etanercept Mouthwash Used for the Treatment of Autologous or Allogeneic Peripheral Blood Stem Cell Transplant or Bone Marrow Transplant Treatment-related Stomatitis?</title>
          <description>Clinical efficacy will be determined by measurement of stomatitis grade and oropharyngeal pain.</description>
          <population>Participants withdrew and analyses were terminated before any data collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>What is the Toxicity of an Etanercept Mouthwash Used for the Treatment of Autologous or Allogeneic Peripheral Blood Stem Cell Transplant or Bone Marrow Transplant Treatment -Related Stomatitis?</title>
        <description>Toxicity will be measured by the incidence of adverse events.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Main Study Participants</title>
            <description>Participants were randomized to one of the following two interventions but the study was not unblinded.
Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.</description>
          </group>
        </group_list>
        <measure>
          <title>What is the Toxicity of an Etanercept Mouthwash Used for the Treatment of Autologous or Allogeneic Peripheral Blood Stem Cell Transplant or Bone Marrow Transplant Treatment -Related Stomatitis?</title>
          <description>Toxicity will be measured by the incidence of adverse events.</description>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pilot Study: Mean Ratings of Oral Mucositis-related Oropharyngeal Pain Intensity on Day 9 (+/- 24 Hours) After Conditioning Chemotherapy (CT)</title>
        <description>Subjects rated pain using the Painometer, a hand-held tool with a visual analogue scale to rate overall pain intensity and a list of 14 sensory and 11 affective pain descriptors ranked by intensity values from 1 - 5. Subjects look at the list of sensory and affective words and select words that describe their pain, including Oral Pain and Oral Pain with Swallowing. . The weighted scores assigned to the words are added to obtain a pain intensity score for the sensory and the affective components. The overall pain intensity is measured on a visual analogue scale which has a range of 1 - 10 with high scores indicating higher pain intensity. The sensory and affective pain scores are otained by adding all of the respective intensity values. The range of possible sensory scores is from 0 - 48 and the range of possible affective scores is from 0 - 37. The sensory and affective scores may be added together to obtain the total pain intensity score, which may range from 0 - 85.</description>
        <time_frame>Day 9 (+/- 24 hours) after conditioning chemotherapy</time_frame>
        <population>One subject was in critical condition at day 9 after CT, preventing data collection at this time</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study: Baseline Scores</title>
            <description>Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.</description>
          </group>
          <group group_id="O2">
            <title>Pilot Study: Day 9 After CT Scores</title>
          </group>
        </group_list>
        <measure>
          <title>Pilot Study: Mean Ratings of Oral Mucositis-related Oropharyngeal Pain Intensity on Day 9 (+/- 24 Hours) After Conditioning Chemotherapy (CT)</title>
          <description>Subjects rated pain using the Painometer, a hand-held tool with a visual analogue scale to rate overall pain intensity and a list of 14 sensory and 11 affective pain descriptors ranked by intensity values from 1 - 5. Subjects look at the list of sensory and affective words and select words that describe their pain, including Oral Pain and Oral Pain with Swallowing. . The weighted scores assigned to the words are added to obtain a pain intensity score for the sensory and the affective components. The overall pain intensity is measured on a visual analogue scale which has a range of 1 - 10 with high scores indicating higher pain intensity. The sensory and affective pain scores are otained by adding all of the respective intensity values. The range of possible sensory scores is from 0 - 48 and the range of possible affective scores is from 0 - 37. The sensory and affective scores may be added together to obtain the total pain intensity score, which may range from 0 - 85.</description>
          <population>One subject was in critical condition at day 9 after CT, preventing data collection at this time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral Pain: Overall pain intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.16"/>
                    <measurement group_id="O2" value="1.38" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Pain: Pain, Sensory Dimension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.60"/>
                    <measurement group_id="O2" value="4.75" spread="11.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Pain: Pain, affective Dimension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.20"/>
                    <measurement group_id="O2" value="3.33" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral Pain: Pain, Sensory and affective Dimensions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.80"/>
                    <measurement group_id="O2" value="8.13" spread="19.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with Swallowing: Overall pain intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.16"/>
                    <measurement group_id="O2" value="2.28" spread="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with Swallowing: Pain, Sensory Dimension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.40"/>
                    <measurement group_id="O2" value="5.48" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with Swallowing: Pain, Affective Dimension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="4.09" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain with Swallowing:Sensory &amp; Affective Dimension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.40"/>
                    <measurement group_id="O2" value="9.61" spread="21.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pilot Study: Percentage of Participants Using Word Descriptors of Sensory and Affective Pain Selected by Subjects on Day 9 (+/- 24 Hours) After Conditioning Chemotherapy</title>
        <description>Participants selected from 14 word descriptors of sensory (S) pain and 11 word descriptors of affective (A) pain.</description>
        <time_frame>day 9 (+/- 24 hours) after conditioning chemotherapy</time_frame>
        <population>One subject was in critical condition at day 9 after CT, preventing data collection at this time</population>
        <group_list>
          <group group_id="O1">
            <title>Pilot Study</title>
            <description>Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.</description>
          </group>
        </group_list>
        <measure>
          <title>Pilot Study: Percentage of Participants Using Word Descriptors of Sensory and Affective Pain Selected by Subjects on Day 9 (+/- 24 Hours) After Conditioning Chemotherapy</title>
          <description>Participants selected from 14 word descriptors of sensory (S) pain and 11 word descriptors of affective (A) pain.</description>
          <population>One subject was in critical condition at day 9 after CT, preventing data collection at this time</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensory words: Cramping, radiation, sharp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory: Splitting, shooting, stabbing, tearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Dull, burning, crushing, pressing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Aching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Hurting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Sore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: torturing, splitting, crushing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S:Cramping, shooting, radiating, stabbing, tearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Dull, aching, pressing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Hurting Group 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Burning, sharp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensory words: Sore Group 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affective words: Terrifying, torturing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affective: Killing, tiring, unbearable, sickening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A: Nagging, agonizing, troublesome, miserable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affective words: Annoying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affective words: Torturing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affective words: Killing, unbearable, terrifying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A: Agonizing, troublesome, tiring, sickening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affective words: Miserable, nagging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Affective words: Annoying Group 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not assessed for the pilot study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Main Study Participants</title>
          <description>Participants were randomized to one of the following two interventions but the study was not unblinded.
Etanercept 2.5 mg in 20cc mouthwash is swished and spit by the participant every 6 hours. The experimental mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant (BMT) Day +14, whichever occurs first.
Placebo 20cc mouthwash is swished and spit by the participant every 6 hours. The placebo mouthwash starts one day before conditioning chemotherapy is administered to the participant and continues until oral pain intensity and stomatitis severity scores are both 0, or by bone marrow transplant day (BMT) Day +14, whichever occurs first.</description>
        </group>
        <group group_id="E2">
          <title>Pilot Study</title>
          <description>Participants were enrolled in the pilot study to collect descriptive data about pain perception and laboratory techniques.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Suzanne Wingate</name_or_title>
      <organization>NINR/NIH</organization>
      <phone>301-827-0982</phone>
      <email>suzanne.wingate@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

